OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

Rhea-AI Summary

OnKure Therapeutics (Nasdaq: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its upcoming participation in two major investor conferences.

The company's President and CEO, Nicholas Saccomano, Ph.D., will participate in:

• A fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025, at 4:20 p.m. ET, with a live audio webcast available online
• A fireside chat at the virtual Stifel Targeted Oncology Forum scheduled for April 8-9, 2025

The Leerink conference presentation will be accessible through a webcast link and the company's website, with replays available for 90 days post-event.

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure’s website at www.onkure.com. Following the event, a replay will be available on the OnKure website for at least 90 days.

• A fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually April 8-9, 2025. Additional information will be available on the OnKure website.
  

About OnKure Therapeutics

OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure- and computational chemistry-driven drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα^H1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.

For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.

Contact:

Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com

FAQ

When is OnKure Therapeutics (OKUR) presenting at the Leerink Partners Conference in 2025?

OnKure Therapeutics will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET.

How can investors access OnKure's (OKUR) Leerink Conference presentation?

Investors can access the live audio webcast through a link provided and the Investors section of OnKure's website at www.onkure.com, with replay available for 90 days.

What investor conferences will OnKure Therapeutics (OKUR) attend in Spring 2025?

OnKure will attend the Leerink Partners Global Healthcare Conference in Miami (March 11) and the Stifel Targeted Oncology Forum (April 8-9, virtual).

Who will represent OnKure Therapeutics (OKUR) at the 2025 investor conferences?

Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will represent the company at both conferences.